1369534-96-2

Basic information

• Product Name: 3-(4-bromophenoxy)Oxetane
• Synonyms: 3-(4-bromophenoxy)Oxetane
• CAS NO: 1369534-96-2
• Molecular Weight: 229.073
• Mol File: 1369534-96-2.mol

Chemical Properties

• CAS DataBase Reference: 3-(4-bromophenoxy)Oxetane(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-bromophenoxy)Oxetane(1369534-96-2)
• EPA Substance Registry System: 3-(4-bromophenoxy)Oxetane(1369534-96-2)

Safety Data

• Hazardous Substances Data: 1369534-96-2(Hazardous Substances Data)

Usage

Type

Oxetane (cyclic ether with a three-membered ring)

Functional Group

4-bromophenoxy group

Applications

Building block in organic synthesis
Development of new materials
Pharmaceutical applications
Agrochemical applications

Unique Properties

Unique structure
Reactivity conducive to diverse applications

Safety Precautions

Handle with care
Adhere to safety guidelines
Minimize potential hazards

Upstream product

• 148430-81-3 oxetan-3-yl methane sulfonate 
• 106-41-2 4-bromo-phenol 
• 7748-36-9 oxetan-3-ol 
• 26272-83-3 oxetan-3-yl 4-methylbenzenesulfonate 
• 1369534-95-1 2-(4-bromophenoxy)-3-tosyloxy-1-propanol 
• 1369534-94-0 2-(4-bromophenoxy)-1,3-diacetoxypropane 

Downstream Products

• 1002129-40-9 C₂₁H₁₇F₃O₄ 
• 1002126-70-6 (2E,4Z)-N-(3-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienamide 
• 1369534-98-4 ethyl (2E,4Z)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienoate 
• 1467057-60-8 6-chloro-5-[4-(oxetan-3-yloxy)phenyl]-1H-indole-3-carboxylic acid 
• 1467060-33-8 6-chloro-5-[4-(oxetan-3-yloxy)phenyl]-1H-indole-3-carbaldehyde 
• 1467060-32-7 5,5-dimethyl-2-[4-(oxetan-3-yloxy)phenyl]-1,3,2-dioxaborinane 

Relevant articles and documents

Mild C–C Bond Formation via Lewis Acid Catalyzed Oxetane Ring Opening with Soft Carbon Nucleophiles

Mild oxetane opening by soft carbon nucleophiles has been developed for efficient C?C bond formation. In the presence of LiNTf2 or TBSNTf2 as catalyst, silyl ketene acetals were found to be effective nucleophiles to generate a wide range of highly oxygenated molecules, which are key substructure in natural products like polyketides. Furthermore, intramolecular oxetane opening by a styrene-based carbon nucleophile via a Prins-type process was also achieved with Sc(OTf)3 as catalyst, leading to efficient formation of the useful 2,3-dihydrobenzo[b]oxepine skeleton.

Nitrogen-containing fused tricyclic derivative and application thereof

The invention discloses a nitrogen-containing fused tricyclic derivative and application thereof, and particularly relates to a novel nitrogen-containing fused tricyclic derivative and a pharmaceutical composition containing the nitrogen-containing fused tricyclic derivative, and the nitrogen-containing fused tricyclic derivative can be used as a selective adenosine A2A receptor antagonist. The invention also relates to a method for preparing the compound and the pharmaceutical composition and application of the compound and the pharmaceutical composition in preparation of drugs for treating adenosine A2A receptor related diseases, especially Parkinson's disease.

CATHEPSIN K INHIBITOR AND APPLICATION THEREOF

The invention relates to capthepsin K inhibitors and uses thereof, specifically relates to a class of compounds having the formula (I) which are used for treating or preventing cathepsin dependent diseases or conditions, specifically, wherein the cathepsin is capthepsin K. The compounds and compositions thereof can be used as bone resorption inhibitors for the treatment of associated diseases.

Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies

We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK

The present invention relates to indole and indazole compounds of Formula (I) that activate 5′ adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.

FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

Discovery of novel 5,5-diarylpentadienamides as orally available transient receptor potential vanilloid 1 (TRPV1) antagonists

We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the 5-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the 5-position increases their ability to penetrate the blood-brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.